Today, scientists presented final results from our Phase I clinical trial of ALN-TTRo1 at the XIII International Symposium on Amyloidosis held in Groningen. Data from this study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels, including both wild-type and mutant TTR protein, in ATTR patients. Knockdown of TTR, the disease-causing protein, was found to be dose dependent, rapid, and durable after just a single dose.
View our presentation (842 KB PDF) View our release Listen to KOL, Dr. Hawkins discuss the ALN-TTR program (recorded Jan. 2012) (27.7MB MP3)Posts Tagged with: Podcasts
December 16, 2011
Podcast: ALN-TTR Phase I Preliminary Results
We recently presented preliminary clinical results for our Phase I study of ALN-TTR01 at the International Symposium on Familial Amyloidotic Polyneuropathy. In this new podcast, Dinah Sah, Ph.D., VP of Research and lead for the ALN-TTR program, discusses the ALN-TTR01 Phase I results she presented at the Symposium, late November. (Length 00:19:32)
Listen to the podcast (22.9 MB mp3) ALN-TTR01 PhI Prelim Results (821 KB PPT)September 8, 2011
ALN-APC for Hemophilia
We have launched our fourth program as part of our Alnylam 5×15 product development strategy. ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5×15 programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform.
Read our press release Listen to our CMO discuss the hemophilia program (13.3MB mp3) View the slides (1.5MB PPT)July 26, 2011
ALN-VSP Podcast Discussing Phase I Clinical Trial
In August 2011, we recorded a podcast around our ALN-VSP program for the treatment of liver cancers. The discussion was led by our own Jared Gollob, M.D., Senior Director of Clinical Research, and Dr. Geoffrey Shapiro, M.D., Ph.D. of the Dana Farber Cancer Institute.
Listen to podcast discussing ALN-VSP and future of Phase I oncology trials (37.6MB MP3) Read our press release ALN-VSP Ph1 ClinicalStudyResults-ASCO2011 (1.2MB PPT)July 24, 2011
“Alnylam 5×15″ Product Strategy
In January 2011, we were very excited to launch our Alnylam 5×15™RNAi therapeutic product strategy. Alnylam 5×15 was established to focus on the development and commercialization of novel RNAi therapeutics addressing genetically defined diseases with major unmet medical need.
Read our press release Listen to our CEO discuss our 5×15 Strategy (4.7MB MP3) Rare Disease Day podcast (7.2MB MP3)June 29, 2011
ALN-VSP Data at 2011 ASCO Meeting
At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement.
Read our press release ALN-VSP PhI ClinicalStudyResults-ASCO2011 (1.2MB PPT) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Listen to Dr. Jared Gollob discuss ALN-VSP data at ASCO 2011 (3.1MB MP3)February 28, 2011
Spotlight on Rare Disease Day Podcast
Disussion with the National Organization for Rare Disorders (NORD) and the Amyloidosis Foundation both fighting to raise awareness and improve health care for those living with rare diseases.
Speakers: Tia Spargo, NORD and Mary O’Donnell, Amyloidosis Foundation
Listen to the Podcast (8MB MP3)January 20, 2011
“Alnylam 5×15″ Podcast
Alnylam’s CEO, John Maraganore, discusses Alnylam 5×15 product strategy focused on the development of innovative RNAi therapeutics for genetically defined diseases addressing major unmet medical needs.
Listen to the Podcast (8MB MP3)